<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03710356</url>
  </required_header>
  <id_info>
    <org_study_id>P170925J</org_study_id>
    <secondary_id>2018-001686-17</secondary_id>
    <nct_id>NCT03710356</nct_id>
  </id_info>
  <brief_title>Evaluating Efficacy and Safety of Danazol in Severe Hematologic or Pulmonary Disease Related to Telomeropathy</brief_title>
  <acronym>ANDROTELO</acronym>
  <official_title>Essai Bayésien de Phase I/II évaluant l'efficacité et la tolérance du Danazol Chez Les Patients Ayant Une Atteinte hématologique ou Pulmonaire sévère liée à Une téloméropathie - ANDROTELO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Constitutional mutations of genes involved in telomere repair and maintenance are responsible&#xD;
      for &quot;telomeropathy&quot; (&quot; Congenital Dyskeratosis &quot;). Attrition of telomeres promotes cell&#xD;
      senescence and genetic instability. The penetrance and severity of organ damage (pulmonary,&#xD;
      hematological, liver, and neurological) is variable, depending on the gene involved, the&#xD;
      generation concerned (anticipation phenomenon) and also environmental factors.&#xD;
&#xD;
      In cases of bone marrow failure, the only curative treatment is hematopoietic stem cell&#xD;
      transplant, often limited by pulmonary and / or hepatic involvement or the absence of a&#xD;
      suitable HLA match donor. The pulmonary phenotype is most often that of idiopathic pulmonary&#xD;
      fibrosis. In severe forms, a lung transplant is proposed in the absence of contraindications.&#xD;
      Anti-fibrotic treatments are not very effective or not evaluated. The observed decrease in&#xD;
      the vital capacity of these patients is 300 ml / year, abnormally high compared to idiopathic&#xD;
      forms. Evolution without transplant is in both situations rapidly unfavorable; the prognosis&#xD;
      after lung or marrow transplant is also worse than that of similar transplants without&#xD;
      telomeres disease.&#xD;
&#xD;
      Danazol has been used for over 4 decades in acquired and constitutional bone marrow failure&#xD;
      in the absence of a therapeutic alternative. In telomeropathy, retrospective data on small&#xD;
      cohorts indicate a haematological response rate of 60-70%. A prospective study in the United&#xD;
      States recently showed a haematological response at 1 year in 78% of cases (10 of 12&#xD;
      evaluable patients) with stabilization of vital capacity. Retrospective data (unpublished) on&#xD;
      patients treated in France have shown more side effects and more frequent treatment&#xD;
      interruptions and eventually weaker haematological response rate. This study aim to evaluate&#xD;
      the benefit of danazol at 12 months on the clinical response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 20, 2018</start_date>
  <completion_date type="Anticipated">October 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>phase ½ therapeutic trial stratified on disease (Severe Hematologic or Pulmonary Disease)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematological response or Pulmonary response at M12</measure>
    <time_frame>12 months</time_frame>
    <description>Response at 12 months is defined according to the initial pathology. Responses is defined as a composite outcome. At least one of the following item should be validated to observe response.&#xD;
For patients with bone marrow failure, the hematological response at 12 months depending on initial cytopenia(s) is defined by&#xD;
1.5 g/dL increase in hemoglobin without transfusion for 2 months&#xD;
And/or increase of 20.10^9/L in platelet count without transfusion for 2 months&#xD;
And/or increase of 0.5.10^9/L in neutrophils count.&#xD;
For patients with pulmonary fibrosis, a decrease of less than 5% in forced vital capacity at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatic tolerance M1</measure>
    <time_frame>1 month</time_frame>
    <description>aspartate aminotransferase blood level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic tolerance M2</measure>
    <time_frame>2 months</time_frame>
    <description>aspartate aminotransferase blood level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic tolerance M3</measure>
    <time_frame>3 months</time_frame>
    <description>aspartate aminotransferase blood level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic tolerance M6</measure>
    <time_frame>6 months</time_frame>
    <description>aspartate aminotransferase blood level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic tolerance M9</measure>
    <time_frame>9 months</time_frame>
    <description>aspartate aminotransferase blood level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic tolerance M12</measure>
    <time_frame>12 months</time_frame>
    <description>aspartate aminotransferase blood level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL cholesterol M3</measure>
    <time_frame>3 months</time_frame>
    <description>Low-density lipoprotein (LDL) cholesterol blood level in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL cholesterol M6</measure>
    <time_frame>6 months</time_frame>
    <description>Low-density lipoprotein (LDL) cholesterol blood level in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL cholesterol M9</measure>
    <time_frame>9 months</time_frame>
    <description>Low-density lipoprotein (LDL) cholesterol blood level in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL cholesterol M12</measure>
    <time_frame>12 months</time_frame>
    <description>Low-density lipoprotein (LDL) cholesterol blood level in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL cholesterol M3</measure>
    <time_frame>3 months</time_frame>
    <description>High-density lipoprotein (LDL) cholesterol blood level in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL cholesterol M6</measure>
    <time_frame>6 months</time_frame>
    <description>High-density lipoprotein (LDL) cholesterol blood level in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL cholesterol M9</measure>
    <time_frame>9 months</time_frame>
    <description>High-density lipoprotein (LDL) cholesterol blood level in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL cholesterol M12</measure>
    <time_frame>12 months</time_frame>
    <description>High-density lipoprotein (LDL) cholesterol blood level in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TG M3</measure>
    <time_frame>3 months</time_frame>
    <description>triglycerides blood level in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TG M6</measure>
    <time_frame>6 months</time_frame>
    <description>triglycerides blood level in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TG M9</measure>
    <time_frame>9 months</time_frame>
    <description>triglycerides blood level in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TG M12</measure>
    <time_frame>12 months</time_frame>
    <description>triglycerides blood level in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA M3</measure>
    <time_frame>3 months</time_frame>
    <description>Prostate-specific antigen (PSA) blood level for men</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA M6</measure>
    <time_frame>6 months</time_frame>
    <description>Prostate-specific antigen (PSA) blood level for men</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA M12</measure>
    <time_frame>12 months</time_frame>
    <description>Prostate-specific antigen (PSA) blood level for men</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary parenchymal abnormalities M6</measure>
    <time_frame>6 months</time_frame>
    <description>Evolution of pulmonary parenchymal abnormalities at CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary parenchymal abnormalities M12</measure>
    <time_frame>12 months</time_frame>
    <description>Evolution of pulmonary parenchymal abnormalities at CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Telomere length</measure>
    <time_frame>12 months</time_frame>
    <description>Evolution of the telomere length by Flow Fish</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cytological and cytogenetic abnormalities</measure>
    <time_frame>12 months</time_frame>
    <description>Appearance of cytological and cytogenetic abnormalities (bone marrow aspiration with cytogenetic)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life evaluation M3</measure>
    <time_frame>3 months</time_frame>
    <description>European Organisation for Research and Treatment of Cancer Quality of Life of Cancer Patients questionnaire (EORTC QLQ-C30, v3.0). The scale range from to 30 to 126 (30 represents the worse quality of life and 126 the best quality of life).&#xD;
http://www.eortc.be/qol/files/C30/QLQ-C30%20English.pdf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life evaluation M6</measure>
    <time_frame>6 months</time_frame>
    <description>European Organisation for Research and Treatment of Cancer Quality of Life of Cancer Patients questionnaire (EORTC QLQ-C30, v3.0). The scale range from to 30 to 126 (30 represents the worse quality of life and 126 the best quality of life).&#xD;
http://www.eortc.be/qol/files/C30/QLQ-C30%20English.pdf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life evaluation M12</measure>
    <time_frame>12 months</time_frame>
    <description>European Organisation for Research and Treatment of Cancer Quality of Life of Cancer Patients questionnaire (EORTC QLQ-C30, v3.0). The scale range from to 30 to 126 (30 represents the worse quality of life and 126 the best quality of life).&#xD;
http://www.eortc.be/qol/files/C30/QLQ-C30%20English.pdf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLCO M3</measure>
    <time_frame>3 months</time_frame>
    <description>Diffusing capacity of the lung for carbon monoxide (DLCO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLCO M6</measure>
    <time_frame>6 months</time_frame>
    <description>Diffusing capacity of the lung for carbon monoxide (DLCO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLCO M9</measure>
    <time_frame>9 months</time_frame>
    <description>Diffusing capacity of the lung for carbon monoxide (DLCO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLCO M12</measure>
    <time_frame>12 months</time_frame>
    <description>Diffusing capacity of the lung for carbon monoxide (DLCO)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Telomere Shortening</condition>
  <condition>Telomere Length, Mean Leukocyte</condition>
  <arm_group>
    <arm_group_label>Danazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Danazol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danazol 200 MG</intervention_name>
    <description>DANAZOL 200 mg as capsules 800 mg/d orally, in 2 doses Duration of treatment: 12 months</description>
    <arm_group_label>Danazol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  with telomeropathy defined by the existence of a deleterious constitutional mutation&#xD;
             of a gene involved in telomere maintenance (TERT, TERC, DKC1, TINF2, RTEL1, PARN, ACD,&#xD;
             NHP2, NOP10, NAF1, WRAP53, CTC1, ERCC6L2, USB1, POT1, DNAJC21 or a newly identified&#xD;
             gene responsible for telomeropathy ),&#xD;
&#xD;
          -  15 years or older,&#xD;
&#xD;
          -  with severe haematological involvement (platelets &lt; 20 G/L or ANC &lt; 0.5 G/L and/or&#xD;
             hemoglobin &lt; 8 g/dL and/or transfusion needs) and/or pulmonary fibrosis with&#xD;
             parenchymal involvement greater than 10% on the CT scan.&#xD;
&#xD;
          -  being able to give informed consent for patients 18 years and older,&#xD;
&#xD;
          -  being able to give consent and have the consent of the holder (s) of parental&#xD;
             authority for children over 15 years,&#xD;
&#xD;
          -  being a beneficiary of social security scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  with HIV infection or active hepatitis B or C infection,&#xD;
&#xD;
          -  with severe hepatic disease: ASAT and/or ALAT &gt; 5N, or direct bilirubinemia &gt; 30&#xD;
             μmol/L, TP &lt;50% (except vitamin K deficiency),&#xD;
&#xD;
          -  having an active or treated tumor pathology for less than 5 years with the exception&#xD;
             of a basocellular carcinoma or a in situ carcinoma of the cervix,&#xD;
&#xD;
          -  with a history of organ or hematopoietic stem cell transplantation or with an&#xD;
             indication of hematopoietic stem cell or organ transplantation within 6 months of&#xD;
             inclusion,&#xD;
&#xD;
          -  with an absolute contraindication to treatment with danazol: active thrombosis or&#xD;
             history of thromboembolic disease, porphyria, severe renal or cardiac insufficiency&#xD;
             (NYHA stage III or IV), androgen-dependent tumor, uncharacterized mammary nodules,&#xD;
             pathological genital hemorrhage of undetermined etiology,&#xD;
&#xD;
          -  who have already received danazol for the treatment of telomeropathy,&#xD;
&#xD;
          -  having received another androgen within a period of less than 6 months,&#xD;
&#xD;
          -  receiving another experimental treatment,&#xD;
&#xD;
          -  receiving another hormonal therapy,&#xD;
&#xD;
          -  receiving simvastatin,&#xD;
&#xD;
          -  having a pregnancy plan and not committing to effective contraception while taking the&#xD;
             treatment,&#xD;
&#xD;
          -  breastfeeding,&#xD;
&#xD;
          -  under guardianship or curators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Flore SICRE DE FONTBRUNE, MD PhD</last_name>
    <phone>142494949</phone>
    <phone_ext>+33</phone_ext>
    <email>flore.sicre-de-fontbrune@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthieu RESCHE-RIGON, MD PhD</last_name>
    <phone>142499742</phone>
    <phone_ext>+33</phone_ext>
    <email>matthieu.resche-rigon@univ-paris-diderot.fr</email>
  </overall_contact_backup>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 10, 2018</study_first_submitted>
  <study_first_submitted_qc>October 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2018</study_first_posted>
  <last_update_submitted>October 15, 2018</last_update_submitted>
  <last_update_submitted_qc>October 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Danazol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

